Applied Statistics

Oncology: AstraZeneca

Total Score People Score Events Score
41 34 31
Date Event Presentation Speakers
January 24, 2016 10th PMWC 2016 Personalized Medicine World Conference TRACK 1 | Microbiome Therapeutics in The Age of Personalized DNA Sequence David Cook
TRACK 4 | Personalised Healthcare in Metabolic Disease RUTH MARCH
December 2, 2015 PERSONALISED MEDICINES & BIOMARKERS 2015 Panelists Chris Harbron, Darren Hodgson
July 23, 2013 EpiCongress Boston Targeting the Substrate Binding Site of Methyltranferases: Structure Based Design of SMYD2 Inhibitors Scott Cowen
June 5, 2013 RNA Therapeutics AZD9150, a Next Generation Antisense Oligonucleotide targeting STAT3 - preclinical and early clinical experience David Blakey
June 4, 2013 World Pharma Congress Cellular Impedance Measures of Cardiomyocyte Cultures for Screening Kinase Inhibitors Matthew Peters
FEATURED PRESENTATION: Predicting, Minimizing and Avoiding Human Adverse Drug Reactions Gerry Kenna
April 6, 2013 AACR Annual Meetings Drug Development Track: New Drugs on the Horizon 1 Co-Chairpersons: Lori S. Friedman, Genentech, Inc., South San Francisco, CA, and Simon Bailey, Pfizer, Inc., San Diego, CA Dennis Huszar
October 31, 2012 The 4th Annual Life Sciences Summit "Collaboration: Working With Industry Means Understanding their Language" Shaun Grady
September 13, 2012 International Society of Gastrointestinal Oncology Summary David Wilson
October 12, 2011 3rd Annual Partnerships in Clinical Trials Asia PANEL DISCUSSION: Overcome the Biggest Challenges in Partnering for Late Phase Trials James Cai
October 25, 2010 4th European Cardiac Safety Conference What are the Mechanisms that can affect QRS and P-R Interval and how do these Translate to Man? Jean-Pierre Valentin
May 4, 2010 Biomarker World Congress 2010 New Era with Targeted Drugs: New Development Approaches are Needed to Achieve Success Geert J.C.M. Kolvenbag
April 30, 2010 Drug Story Development of a Portfolio of Therapeutic Antibodies for Oncology Combining Xenomouse and Display Technologies David Blakey
February 22, 2010 2010 PERSONALIZED MEDICINE PARTNERSHIPS CONFERENCE Strengthening Big Pharma's Personalized Medicine Pipeline via Partnerships with Diagnostics Companies Cecilia Schott
June 10, 2009 Inaugural Risk Management and Drug Safety Strategies for Better Decision Making Steps to Identify Earlier and Better Assessment of Potential Risk of Compound in Development Lewis Kinter
June 9, 2009 Cell and Tissue-Based Assays for HTS Screening Bone Marrow Toxicity Using a Tiered Approach David Brott
April 7, 2009 Kinase Inhibitor Chemistry - Charting the Chemical Space Identification of Potent and Selective Inhibitors of Trk Kinases Tao Wang
February 10, 2009 10th Annual Phase I Clinical Trials New approaches for effectively managing complex Phase I trials Harsukh , Parmar
New directions for improving education and training for Phase I professionals Susanne Kihlblom
Achieving significant cost reduction through innovative Phase I outsourcing Susanne Kihlblom
January 26, 2009 Translational Cancer Medicine VANDETANIB : Pretreatment Circulating VEGF Levels as A Predictive Biomarker of Efficacy in NSCLC Patients Treated with Vandetanib Anderson Ryan
January 5, 2009 High Content Analysis Application of Novel Multiparametric High-Content Toxicity and Phenotypic Assays: Integration with Advances in Automation, Image Analysis, Multivariate Statistics and in silico Modeling Neil Carragher
Evaluation of Cellular Impedance Assays for Assessing Ligand-Specific GPCR Signaling in Drug Discovery Matt Peters
December 4, 2008 BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008) Session Chair :Track 1-10 James Jianguo Li
Small Molecule Inhibitors Targeting Mutation Driven Cancers :Track 2-4 (I) Jeannie Hou
November 26, 2008 Speed and Safety in Drug Discovery Humanising drug discovery to make earlier & better Stop/Go decisions in Pharma R&D Paul Newbold
November 17, 2008 BIO-Europe 2008 Critical Issues to Consider when Entering the U.S. Market and Partnering with U.S. Companies Chris Yochim
A Day in the Life of Experienced Dealmakers – Year 6! Shaun Grady
A Day in the Life of Experienced Dealmakers – Year 6! Shaun Grady
September 29, 2008 Genomic Biomarkers Personalized Healthcare – Where Are We Now? Ruth E. March
April 28, 2008 Clinical Development of Therapeutic Antibodies Development of a New Fully Human Anti-CD20 Gadi Bornstein
Preclinical and Clinical Safety of Monoclonal Antibodies Richard Knight
April 27, 2008 Phage Display of Antibodies and Peptides Development of a Portfolio of Therapeutic Antibodies for Oncology Combining Xenomouse and Display Technologies David Blakey
March 31, 2008 China 2008 Pharmaceutical R&D Summit Track II Embarking on a Long March for Early Drug Development in China James Cai
March 25, 2008 R&D Risk Mitigation Negotiating the Partnership William F Mongan
March 25, 2008 Clinical Trials Asia Utilizing and Integrating Global Clinical Study Local Data from China to Mutually Support Global and Local Applications in Order to Benefi t Unmet Medical Needs James Cai
November 29, 2007 Fourth Annual In Vivo Molecular Imaging: Bridging the Gap from Discovery to Clinical Applications Nov (29-30) Clinical Applications (13:40-17:30) Chi-Ming Lee
Clinical Applications: PET as a Translational Tool for CNS Drug Development (15:20-15:50) Chi-Ming Lee
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) BIOMARKERS IN PERSONALIZED MEDICINE: Quantifying the Additional Benefits of Proteomics in Patient Selection (16:00-16:30) Chris Harbron
BIOMARKERS IN PERSONALIZED MEDICINE: Genome-Wide Pharmacogenetic Investigation of Adverse Events: A Case Study (13:15-13:45) Ruth E. March
BIOMARKERS IN PERSONALIZED MEDICINE (13:10-17:00) Ruth E. March, Chris Harbron
BIOMARKERS FOR SAFETY ASSESSMENT: Biomarkers of Nephrotoxicity in Toxicology and the Clinic (14:00-14:30) Graham Betton
November 5, 2007 15th Annual Biotech Investing Conference (Nov 5-6) SURVIVAL OF THE FITTEST: Big Biotech & Pharma to Access External Innovation(11:30- 12:30) Maggie Flanagan LeFlore
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.